Why the study?
Does cryoprecipitate plus intra-arterial thrombin and epsilon aminocaproic acid induce tumor thrombosis in patients with Kasabach-Merritt syndrome?
Does cryoprecipitate plus intra-arterial thrombin and epsilon aminocaproic acid induce tumor thrombosis in patients with Kasabach-Merritt syndrome?
Targeted interventional angiography with aminocaproic acid and thrombin can successfully treat Kasabach-Merritt syndrome while avoiding a systemic antifibrinolytic state.
May support targeted therapy in Kasabach-Merritt syndrome; hypothesis-generating and should not yet change practice.
A patient with the Kasabach-Merritt syndrome with disseminated intravascular coagulopathy and congestive heart failure due to a giant hepatic cavernous hemangioma achieved thrombosis of his tumor with a combination of cryoprecipitate plus intra-arterial thrombin and epsilon aminocaproic acid. This was documented by an absence of Indium 111-labelled platelet sequestration, marked decrease in thrombin:antithrombin complex generation, and normalization of platelet count and fibrinogen. Interventional angiography with aminocaproic acid and thrombin is advocated in patients whose tumors are amenable to such an approach so as to avoid a systemic antifibrinolytic state.
No takes yet. Share an insight, caveat, or question.
Stahl et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: